Video

Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients With High-Risk Cytogenetics: IKEMA Subgroup Analysis

Author(s):

Thomas Martin, MD, University of California San Francisco

Expert hematologist-oncologist Thomas G. Martin, MD, shares data from the IKEMA subgroup analysis in patients with relapsed multiple myeloma treated with isatuximab, carfilzomib, and dexamethasone.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments
Video

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Apr 23rd 2025 - Apr 24th 2026

online-activity
View More
Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2
Video

Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2

Apr 23rd 2025 - Apr 24th 2026

online-activity
View More
Addressing Unmet Needs in HER2+ Metastatic BTC
Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 18th 2025 - Apr 19th 2026

online-activity
View More
Related Content
Multiple Myeloma | Image Credit: © Mikkel – stock.adobe.com
April 24th 2025

Retrospective Data Show Improved Efficacy but Higher Toxicity With Cilta-Cel vs Ide-Cel in R/R Myeloma

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Five Under 5: Top Oncology Videos for the Week of 4/13
April 20th 2025

Five Under 5: Top Oncology Videos for the Week of 4/13

Paul G. Richardson, MD
October 2nd 2023

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

Image credit:© Maris– stock.adobe.com
April 17th 2025

Belantamab Mafodotin–Based Combos Win UK Approval for R/R Myeloma

Multiple Myeloma | Image Credit: © LASZLO – stock.adobe.com
April 14th 2025

Addition of Daratumumab to Lenalidomide Maintenance Boosts MRD-Negative Conversions in Myeloma Following ASCT